Familial breast cancer and the hCHK2 1100delC mutation: Assessing cancer risk

14Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Germline mutations in the human checkpoint gene, hCHK2, were first identified in 1999 in cases of Li-Fraumeni syndrome. Recent studies have demonstrated that the hCHK2 1100delC mutation acts as a low-penetrance tumour suppressor gene in familial breast cancer not associated with mutations in BRCA1 or BRCA2. The present article describes the published studies on hCHK2 1100delC and addresses some of the key questions raised.

Cite

CITATION STYLE

APA

Varley, J., & Haber, D. A. (2003). Familial breast cancer and the hCHK2 1100delC mutation: Assessing cancer risk. Breast Cancer Research, 5(3), 123–125. https://doi.org/10.1186/bcr582

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free